Zyvox Safety Alert Undercuts PhRMA Good News Events
This article was originally published in RPM Report
Talk about bad timing. A March 16 safety alert issued by the Food & Drug Administration regarding Pfizer Inc.'s antibiotic linezolid (Zyvox) couldn't have come at a worse time. If there was any doubt left on the point, it is gone now: drug safety will be the dominant theme for the pharmaceutical industry in 2007.
You may also be interested in...
FDA is being more proactive about issuing safety warnings. But, as GSK's experience with Advair shows, what looks like bad news to Wall Street may not matter as much to physicians. FDA is well aware of the limitations of its risk communication techniques, but for now the agency is commited to transparency.
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.
Whether CME for pain management has the intended impact on prescribing is likely focus of new ‘suite of studies’ intended to assess the opioid REMS program. The challenges for FDA include teasing out the impact of the risk management program amid all the other public health efforts on opioids.